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Abstract 
Background: Clinicians and patients find prognosis and end-of-life care discussions 
challenging. Misunderstanding one’s prognosis can contribute to poor decision-making 
and end-of-life quality-of-life. A Question Prompt List (QPL – booklet of questions patients 
can ask clinicians) targeting these issues may help overcome communication barriers. 
None exists for end-of-life discussions outside the palliative care setting.  
Aim: To develop/pilot a QPL facilitating discussion/planning of end-of-life care for 
oncology patients with advanced cancer from Australia and the USA and explore: 
acceptability, perceived benefits/challenges of using the QPL, suggestions for 
improvements and the necessity of country specific adaptations. 
Design: An expert panel developed a QPL targeting prognosis and end-of-life issues. 
Australian/US semi-structured interviews and 1 focus group elicited feedback about the 
QPL. Transcribed data were analysed using qualitative methods. 
Setting/participants: Thirty-four patients with advanced cancer (15 Australian/19 US) and 
13 health professionals treating such patients (7 Australian/6 US) from 2 Australian and 1 
US cancer centre participated.  
Results: Most endorsed the entire QPL, though a minority queried the 
utility/appropriateness of some questions. Analysis identified four global themes: 1) 
reinforcement of known benefits of QPLs, 2) appraisal of content and suggestions for 
further developments, 3) perceived benefits and challenges in using the QPL and 4) 
contrasts in Australian/US feedback. These contrasts necessitated distinct Australian/US 
final versions of the QPL.  
Conclusions: Participants endorsed the QPL as acceptable and useful. Feedback 
resulted in two distinct versions of the QPL, accommodating differences between 
Australian and US approaches to end-of-life discussions, highlighting the appropriateness 
of tailoring communication aides to individual populations. 
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Introduction 
Over a third of adult patients with cancer die prematurely of their disease, many 
experiencing sub-optimal end-of-life care. [1,2] Patients often do not discuss prognosis or 
end-of-life care with their doctor or family [3-5] though most desire such discussions [6]. 
This can contribute to inappropriate end-of-life care choices, increased suffering and 
possibly decreased survival. [7,8]  
 
Clinicians may be unsure how much patients want to know and worry about destroying 
hope [9] while patients may not know what to ask or how or feel unprepared for the 
answers [10]. Question Prompt Lists (QPLs – booklets containing categorised lists of 
useful questions patients can ask their clinician) can assist in overcoming these barriers. 
Increased patient question asking and decreased unmet information needs have been 
seen in randomised controlled trials of QPLs [11,12] with patients finding them more 
helpful than receiving written information alone as they assist them with formulating 
questions. [13] 
 
QPLs have been developed for patients seeing medical oncologists, radiation oncologists 
or surgeons for the first time, [14,15] and patients and carers newly referred to palliative 
care. [16] No QPL has been developed for patients with advanced cancer outside the 
palliative care setting. Such patients newly face deterioration and eventual death, 
experiencing challenges in eliciting and adapting to information about prognosis and end-
of-life issues. As they remain well enough to participate in Advance Care Planning (ACP), 
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ensuring their end-of-life needs and wishes are respected, they have the potential to 
benefit greatly from such a QPL.  
 
Little cross-cultural data exists regarding such communication aids [17] and health system 
differences and cultural factors may influence content, delivery and impact of QPLs. While 
both favouring disclosure and discussion of prognosis and end-of-life issues, [18] Australia 
and the United States of America (US) have marked differences in end-of-life healthcare 
models, [19,20] including the presence in Australia and absence in the US of national end-
of-life care policies, differing availability of palliative care consultations and services, and 
dissimilar conditions of access to care and location of care facilities. [20] 
 
The QPL piloted in this paper was developed to facilitate discussion and planning of end-
of-life care and associated issues with Australian and US patients who have advanced 
cancer and are likely to die within 12 months. Content was guided by factors identified as 
important at the end-of-life by patients, family, physicians and care providers [21,22]. We 
sought to explore the acceptability, perceived benefits and challenges of using this QPL, 
elicit suggestions for improvement and determine the necessity of country specific 
adaptations of the QPL. 
 
Methods 
Initial question prompt list development 
Questions were developed and refined in Australia by an expert panel of seven health 
communication researchers and health professionals from psychology, medical oncology, 
palliative care, critical care nursing and family medicine disciplines. Guided by panel 
members’ knowledge, selected relevant literature was consulted and several existing 
QPLs were sourced from database searches of studies published since 1950 or requested 
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from authors. [14-16,21-24] Where possible, items were adapted from existing QPLs if 
they focussed on issues relevant for the target population and purpose of the QPL 
including; prognosis, treatment options and decisions with non-curative intent, end-of-life 
issues, ACP and supportive or palliative care services for the patient, carer or family. 
Where existing items covering target issues were not available, new items were drafted. 
The panel then established item and topic orders in the QPL, drafted introductory and 
instructional texts to precede the first section and reviewed the content and structure of 
this initial QPL for clarity and acceptability. US researchers reviewed the initial QPL to 
ensure cultural appropriateness in their setting. Several changes were necessary, 
including the removal or reordering of some questions and sections and use of US rather 
than Australian idiomatic expressions. The resulting Australian and US initial QPLs are 
presented in Appendix 1. 
 
Participants and procedure 
English-speaking adult patients with advanced, incurable cancer and a life expectancy 
(assessed by their oncologist) of less than 12 months, and oncology and palliative care 
doctors and nurses who treat such patients participated. Members of the research team 
identified and invited health professionals meeting selection criteria from one US and two 
Australian treatment centres to participate in the study. Consenting oncologists identified 
consecutive patients meeting selection criteria when they attended consultations and 
research assistants approached identified patients to obtain informed consent to 
participate.  
 
Participants elected to join a focus group or complete an individual, semi-structured 
interview conducted by research assistants trained in qualitative methods. Interviews were 
offered to facilitate the participation of individuals who were unable or unwilling to join a 
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focus group. Participants completed a short questionnaire eliciting demographic and 
disease or professional details and were given the QPL and a short time to become 
familiar with the content before beginning the interview/focus group. In accordance with 
established qualitative research protocols, sampling was discontinued when information 
redundancy was reached, with three consecutive interviews yielding no additional 
information. [25] Each interview and the focus group were audio-recorded and transcribed 
verbatim. 
 
Sydney South West and Northern Sydney Central Coast Area Health Services Ethics 
Committees in Australia and the University of Rochester Research Subjects Review Board 
in the US granted ethical approval.  
 
Measures and interviews/focus group 
Elicited demographic details included age, gender, educational attainment, primary tumour 
site and treatments received for patients, and age, gender, experience, communication 
training and specialty for health professionals. During the interview/focus group, 
participants were invited to comment on the clarity, relevance and appropriateness of the 
QPL content, potential barriers and facilitators to its use, and suggest any additions, 
deletions and changes they felt were appropriate. 
 
Analysis 
The research team reviewed and interpreted transcripts using thematic text analysis with 
an inductive, data-driven approach, [25-27] managed with Atlas.ti. [28] Consistent with this 
method, Australian and US researchers (AW/BM) independently developed codes 
representing underlying meanings in the text. Interview and focus group data did not 
appear to systematically differ by participation method and were analysed collectively. The 
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research team regularly compared and discussed code names and definitions to resolve 
areas of disagreement. A random sample of 12 transcripts was double coded to ensure 
agreement between the two coders. Through iterative reading of data grouped by codes, 
recurrent themes and illustrative examples were established. Comparison was made 
between coded Australian and US transcripts to discern points of commonality and 
divergence. Successive rounds of iterative discussion and resolution of code names, 
definitions and themes and review of the coding process by team members not directly 
involved in developing the coding framework ensured methodological rigour. [29] 
 
Results 
Participant Characteristics 
Fifteen Australian and 11 US patients completed individual interviews and 8 US patients 
joined a focus group (see Table 1). Australian patients were predominantly male (80%), 
mean age 67 years. Most had primary lung cancer (60%), and 11 of the 15 had received 
chemotherapy, 6 radiotherapy and 7 surgery. US patients were predominantly female 
(68%), mean age 58 years. While individual US data were not obtained, primary diagnoses 
included colon, breast, lung, pancreas or prostate cancers with progression during 
chemotherapy. 
Insert Table 1 here 
 
Seven Australian and 6 US health professionals completed individual interviews (see 
Table 2). Australian health professionals were predominately male (57%), mean age 45 
years. Two were medical oncologists, one a radiation oncologist, three were oncology 
nurses and one a palliative care nurse with 13 years experience in their field on average. 
Three had completed postgraduate communication skills training. US health professionals 
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were predominantly female (67%). All were medical oncologists with 16 years experience 
on average. Four had completed postgraduate communication skills training.  
 
Insert Table 2 here 
Themes 
There was broad commonality in patients’ and health professionals’ responses and the 
themes described below reflect both participant groups. Variations in participants’ 
feedback did not appear to be systematically related to demographic factors. Differences 
between the two groups’ feedback are highlighted where present. Four global themes 
were identified: Reinforcement of known general benefits of QPLs, Appraisal of the QPL 
content and suggestions for further developments, Perceived benefits and challenges in 
using a QPL focussing on end-of-life issues and Contrasts between Australian and US 
feedback. These themes are discussed in detail below and illustrated with participants’ 
quotes, chosen for their ability to succinctly illustrate themes and sub-themes. Quotes 
represent the perspectives of multiple participants. 
 
Reinforcement of known general benefits of QPLs 
Patient and health professional participants provided largely positive feedback about the 
QPL, reinforcing previously identified general benefits of QPLs. Some indicated that the 
QPL could ensure patients’ information needs would be met if their doctor were not an 
optimal communicator while others noted it would help patients remember questions they 
wished to ask.  
 
Helpful if doctor is not an optimal communicator – “You’ve got ten thousand questions 
running around in your head… if you have a specialist not exactly full of people skills, then 
this would (help the discussion)” (Au Patient 01) 
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Help to remember questions – “You go in and you think ‘I’ll ask them this’ and then you 
forget.  And then you go home and you think ‘should’ve asked that…’ So if you’ve got (this 
and) you ask a couple of questions each time, that’s not a bad idea” (Au Patient 03) 
 
Patients suggested this could help manage information overload commonly experienced in 
this setting, with some describing independently writing down questions for their doctor for 
this purpose. Patients also noted that the QPL prompted consideration of issues they were 
previously unaware of. 
 
Help to manage information overload – “I think this definitely a good booklet. It would be 
very helpful for people that don’t write down questions before they go into appointments 
with their oncologist” (US Patient 01) 
Prompted consideration of new issues – I never have and probably never would have 
thought to ask a question like that. So, that’s a good one to actually ask. (US patient 09) 
 
Appraisal of the QPL content and suggestions for further developments 
Patients and health professionals mostly endorsed the content of the QPL, indicating that 
it was comprehensive and achieved its aims. Most questions were regarded as 
appropriate and important, with only a small minority critiquing some items.  
 
Appropriate content – “I think they’re all good questions.  I think some patients would find 
them quite difficult (but) it doesn’t mean they shouldn’t be asked.” (Au Health Professional 
01) 
 
Several participants, principally in the US patient sample, displayed ambivalence towards 
end-of-life questions (e.g. US Initial Version – section 4 “What I can expect” and section 6 
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“If treatment doesn’t work” and Australian Initial Version – section 1 “My cancer and what 
to expect in the future” and section 6 “Preparing for the end-of-life”), mostly indicating that 
while they were “good,” they would perhaps be more relevant later or for other people.  
 
Good but more relevant for others – “They were excellent questions, they don’t apply to 
me but other people” (Au Patient 02) 
Good but more relevant at another time – “There’s some questions in there you don’t 
really want to ask – not yet, maybe later” (Au Patient 10) 
 
Some questions were considered personally irrelevant due to patients’ outlook (e.g. Who 
can I talk to about my religious, spiritual or emotional needs?), coping style (e.g. Is it 
possible to give me a time frame?) or a high likelihood that information would be 
volunteered without a specific query (e.g. What kind of cancer do I have?).  
 
Personally irrelevant due to outlook – “Well, basically I think I've got a good doctor in Dr 
(name) and I'm happy to be guided by her” (Au Patient 06) 
Personally irrelevant due to coping style – “I have never had difficulty making an 
important decision ever in my entire life… you simply see what the situation actually is and 
you fit in with it… I’m not a discusser of these matters with anyone” (Au Patient 08) 
Personally irrelevant due to volunteered information – “Well, they tell me that right 
when I walk in. I don’t even ask those questions” (US Patient 01) 
 
Patients and health professionals alike indicated that an oncologist might not be the ideal 
person to ask certain questions, citing greater availability or expertise from other 
information sources (e.g. US Initial Version – section 5 “What I can do” and Australian 
Initial Version – section 5 “Support for me and my family” financial assistance question).  
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Doctor potentially not ideal person to ask – “I can’t understand what this (financial 
support) part is… What can (the doctor) do for you? (Au Patient 10) 
 
Importantly, all participants advocated retaining rather than eliminating questions, even 
those thought to be irrelevant or difficult to approach or answer, as different patients or 
their own shifting priorities might render them useful. 
 
Perceived benefits and challenges in using a QPL focussing on end-of-life issues 
All patients and most health professionals endorsed the overall beneficence of this QPL 
for this point in the cancer trajectory with many describing specific benefits and challenges 
they envisaged in using an end-of-life focussed QPL. Several patients indicated they 
would have benefitted from receiving this QPL when first informed that their cancer was 
incurable and that this was the ideal time to provide the QPL. 
 
Personally beneficial and should be used near disclosure of incurability – “As an aid 
I think it’s very effective and I only wish I had that in my hot little hand when I was first told 
about it… I think it might have saved a lot of grief” (Au Patient 01) 
Should be used early – “I wish we would have gotten something like this when we first 
started, just something this basic. (US Patient 03) 
 
Some reported that they would consider discussing issues such as ACP and palliative care 
having read the QPL. Additionally, one patient highlighted the potential importance of 
these questions to carers, describing the transference of illness burdens from patient to 
carer as the disease progressed. 
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Would now consider discussing palliative care, ACP – “(Advance care planning) I 
haven't even considered… I will have to start looking at that… Is there a way to plan and 
document my wishes?  Well, I can tell my executor who's a friend of 40 years; mind you 
she may not know that I was in hospital… I really need to talk to somebody about this. And 
I will.” (Au patient 06) 
Importance to carers – “I think these questions definitely need to be in the pamphlet… 
not only for the patient but for the caregiver as well if there is one involved… most of the 
stress will probably be put on them and not the patient” (US Patient 05) 
 
Interestingly, while patients emphasised that the QPL would encourage more questions 
during consultations, helping them acquire more information, some health professionals 
were reluctant to see increased question asking, highlighting the need to moderate it 
during consultations due to ubiquitous time pressures. 
  
Health Professionals advocating need to moderate patient question asking – “I think 
that you should stress that although these are all important questions; these may be 
addressed over several visits, rather than just one visit” (US Health Professional 01) 
 
One patient noted that questions related to life expectancy may be harmful if incorrect 
information was given, delivered insensitively, or if the recipient were young. Other 
participants appeared similarly cautious about discussing life expectancy, though none 
explicitly identified aspects deserving caution, despite interviewers’ prompts to elaborate. 
  
Life expectancy questions deserve caution – “That could really hurt some people. 
When I was 21, I was told I had six months to live, incurable. Not worth operating on 
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because it’d be spread throughout my body… I nearly went out and went under a train” 
(Au Patient 06) 
 
Several patients also highlighted the potential futility of asking questions. Some noted that 
oncologists might not respond to queries or do so in an unhelpful or undesirable way. 
Others cited spiritual or epistemological perspectives when explaining this sense of futility. 
 
Patients’ sense of futility in asking questions due to response – “All doctors and 
specialists are the same, they don’t like to say, “you can expect this,” because people are 
different in their responses to different diseases, and so I don’t get quite the responses I’d 
like to hear… while (my doctor) is very supportive and helpful, she’s a bit disinclined to 
say, “You’ll still be around this time next year.” (Au Patient 05) 
Patients’ sense of futility in asking questions due to spiritual perspective – “When 
they answer it precisely the get it wrong... The one thing doctors can’t ever tell you for 
sure, when you are coming into this world and when you’re going out… I think there is a 
point at which medicine doesn’t have the ultimate answer.” (US patient 12) 
 
Importantly, both patients and health professionals acknowledged the need to train doctors 
to communicate prognostic information appropriately as a crucial counterpart to the QPL. 
 
Training influences prognostic discussions – “I make it a point to bring (prognosis) up. 
I say we should talk about the bigger picture too. Most (patients) receive that very 
positively… I think the majority of oncologists might not do it that way…I think it has to do 
with the training” (US Health Professional 02) 
Need to train doctors – “People need to be able to ask the question (about timeframes) 
and the doctors need to be trained on how to respond” (US Patient 16) 
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Contrasts between Australian and US feedback 
Although Australian and US participants were similarly positive about the QPL, US 
participants seemed more ambivalent and wary of discussing the issues raised than 
Australian participants. US patients generally displayed more hesitation, using more 
euphemisms when discussing sensitive content, such as prognosis, dying or their cancer 
in general, while most Australian patients used more blunt language. 
  
US patients’ use of euphemistic language – “You are in a hospice with a morphine drip 
and you just kind of drift away” (US Patient 01) 
Australian patients’ use of blunt language – “Well you’d like to know (what will happen) 
wouldn’t you… you know bald, laying dead on a bed in the hall…” (Au Patient 02) 
Australian patients’ use of blunt language – “Preparing for the end-of-life - I thought 
‘this poor devil has just been told they’ve got a terminal disease, that’s a bit heavy to throw 
at them…’ But they have to know they’ve got a terminal disease… you can’t sugar-coat the 
phrase any other way” (Au Patient 01) 
 
US health professionals seemed less positive than Australian health professionals about 
questions related to prognosis. Some indicated that unless patients specifically raised the 
topic, they would not necessarily discuss it.  
 
Australian Health Professionals more positive about prognosis – “I try from the word 
go to be realistic about prognosis and stuff so that it doesn’t come as the big shock.  So if 
a patient has metastatic disease I’m very up front from the first consultation and say, we 
cannot cure this.  The best we can hope to do is to control it for a period of time, but it’s 
going to get smarter than the treatment that we have.” (Au Health Professional 01) 
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US Health Professionals less positive about prognosis – “Any time I’m thinking that a 
patient needs a change in therapy or if they need an additional discussion on 
chemotherapy, I go through a lot of things that are relevant to the chemotherapy but try not 
to get into prognosis unless people ask, because it’s such an imprecise science” (US 
Health Professional 03) 
 
Additionally, some US health professionals advocated not including ACP related items due 
to QPL length and complexities and regional variations in US law related to this topic. They 
also displayed stronger opinions about which questions were more appropriately directed 
to other sources of information than their Australian counterparts. 
 
US participants’ stronger opinions about what not to ask oncologists – “I would say, 
‘I’m not going to answer these questions (about support services) for you. We have a 
resource centre, my nurse knows some of these questions, and there’s a social worker” 
(US Health Professional 01) 
 
Final QPL text development 
Two final versions of the QPL were required to accommodate culturally appropriate 
language needs and contrasting Australian and US feedback regarding sensitive content. 
Overall, participants from both groups advocated retaining QPL content, however two 
items regarding treatment costs and affordability were ultimately irrelevant for the 
Australian QPL given the availability of public healthcare for seriously ill Australian 
patients, hence they were removed. The final US QPL prepared the reader with less 
sensitive content, reserving questions about prognosis for the fourth section in response to 
apparent reluctance amongst US participants to discuss that issue. Conversely, Australian 
participants reacted positively to these questions and they remained in the first section of 
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the Australian QPL. Both Australian QPLs contained questions about ACP and 
documenting end-of-life care preferences. These were well accepted, with patients 
indicating that they would be useful, prompting consideration of new issues. Some US 
participants suggested that end-of-life care preference documentation questions in 
addition to existing prognosis and timing of end-of-life discussions questions might 
decrease QPL acceptability and utility. Considering the positive reaction of Australian 
participants to this content and the importance of discussing these issues, two items 
regarding ACP were included in an additional section following the prognosis content in 
the final US QPL. Several changes were also made to the wording of various items and 
the introductory texts of both final QPLs in response to feedback and review by the 
research team. Australian and US final QPLs reflecting these developments are presented 
in Appendix 2. 
 
Discussion 
Despite concerns that patients with advanced cancer do not want or will be distressed by 
prognosis and end-of-life information, [6,9] QPLs addressing these issues were well 
accepted by both patients and health professionals. Participants’ positive responses to 
these QPLs suggest they could be effective tools for overcoming barriers to end-of-life 
discussions. 
 
Participants highlighted various benefits of these QPLs. Patients illustrated how they could 
ameliorate information overload commonly experienced [30] when first informed they had 
incurable cancer or transitioning from curative to palliative treatment. Many wished they 
had received the QPL early in their disease trajectory at one of these critical moments. 
Several suggested such critical moments where information overload is likely were the 
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ideal time to introduce the QPL, adding that it could bring much needed structure to ones’ 
communication about their care 
 
Interestingly, while many patients were positive about the QPL content, some indicated 
they would delay asking certain questions. Though the point of QPL delivery is undeniably 
important, patients’ internal determination of when to ask these questions is perhaps more 
influential in dictating when such discussions will occur. While we have previously 
highlighted the role of appropriate timing in patients’ readiness for such discussions, [31] 
patients’ decisions about appropriate timing require further investigation. 
 
Despite recommendations that clinicians initiate these discussions, [32] our participants 
noted how uncertainty and collusion to remain optimistic could hinder this. [5] Most felt that 
the QPL could beneficially facilitate and normalise end-of-life discussions by prompting 
patients to raise prognosis, end-of-life issues and ACP. Importantly, several Australian and 
US patients indicated that the QPL had prompted consideration of new issues with some 
indicating that they would definitely ask those questions in the near future, particularly 
regarding palliative care and ACP. Consistent with previous studies, [12] our findings 
support the likelihood that these QPLs will promote patient involvement in consultations, 
supporting open communication between health professionals and patients with advanced 
cancer, prior to consideration of a purely palliative approach. 
 
Though rarely mentioned, participants identified potential challenges in using these QPLs 
including the irrelevance, inappropriateness or futility of asking certain questions. Patients 
tended to consider questions irrelevant if they concerned routinely given information, 
including cancer type, metastasis or details of diagnostic tests; or if they were generally 
disinclined to ask questions during consultations. Financial concern and insurance 
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focussed questions were most commonly identified as inappropriate to ask oncologists, 
though this was more evident amongst US than Australian participants. Some patients 
were also ambivalent towards prognosis and end-of-life care questions, perhaps reflecting 
a struggle between wanting clarity and maintaining hope, a perceived dichotomy often 
reported by patients and health professionals. [3,6,33,34] 
 
Some patients articulated concerns regarding the futility of asking certain questions. 
Several expressed beliefs that oncologists were unable to quantify ones’ prognosis, hence 
seeking estimates had little value. Highlighting the benefits of understanding ones’ 
prognosis whilst acknowledging known systematic prognostication inaccuracies [35] may 
therefore improve the worth of prognostic discussions for patients.  
 
Other patients suggested that questions may be disregarded or answered inappropriately 
and that this would make using the QPL challenging. Indeed, evidence suggests QPLs are 
only effective when all stakeholders appropriately support their use and health 
professionals have the skills and willingness to communicate information accurately and 
compassionately. [11] Both patients and health professionals recognised the importance of 
communication skills, highlighting the need to train oncologists to answer prognosis and 
end-of-life related questions in addition to providing the QPL to patients, supporting a 
growing consensus regarding the importance of end-of-life communication skills training 
for health professionals [36] and the need to better equip oncologists to estimate and 
discuss life expectancy. [37] Such training has demonstrated improvements in clinician 
skills including estimating and framing prognostic information, responding to emotions and 
delivering bad news [38,39] with enduring effects in clinical settings. [40] 
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Participants made little mention of training patients and carers in QPL use. Nurse-led 
patient communication training and assistance programs for the end-of-life context, such 
as the SUPPORT intervention [2], have shown promise, but have been criticised for 
lacking concrete tools to assist with communication. This QPL could be utilised within such 
an intervention, giving patients and carers the opportunity to receive personalised 
assistance in exploring and using the QPL. Indeed, it has been suggested that 
communication training for patients may moderately but significantly increase their 
question asking [41] though evidence for training in QPL use has been less robust. [11] 
 
The lack of enthusiasm for prognosis and end-of-life related items among some US 
participants relative to their Australian counterparts was surprising as previous studies 
have grouped Australian and US populations together as cultures in favour of medical 
disclosure in contrast to Europe and Asia cultures where it is less favoured. [18]  
Accommodating multiple populations, even as similar as Australia and the USA, when 
creating intervention materials containing sensitive content, such as end-of-life care, may 
ultimately be unfeasible, though further exploration is required. Of note were study 
interviewers’ reports that US patients presented as less impaired by their disease than 
Australian patients, raising the possibility that US/Australian patient subgroup differences 
were related to functional status or physical wellbeing rather than cultural issues. US 
patient responses might conceivably have more closely resembled those of Australian 
patients had they been sicker. This would not account for differences between US and 
Australian health professionals’ appraisal of some questions nor US health professionals’ 
stronger aversion to receiving queries that could be answered by others, suggesting 
genuine differences between the two healthcare cultures. As no patient performance 
status or survival data were available, this issue deserves further exploration. 
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Australian QPL questions about ACP and documenting end-of-life care preferences were 
well accepted. Patients indicated that they would be useful and the considerable benefits 
afforded by ACP of allowing patients to express their preferences for future care, helping 
them and their carer to maintain autonomy and authority in treatment decisions once they 
become incapacitated are well acknowledged. [42] The initial US QPL contained no 
questions about documenting ACP and US participants suggested further focus on 
documenting end-of-life care in the context of prognosis discussions might decrease 
acceptability and utility. While ACP is equally important in the US, the political, social and 
legal climate there is somewhat polarised regarding physicians’ potentially coercive role in 
end-of-life discussions and there is considerable variation in state laws regarding these 
issues. [43] However, given the value of discussing end-of-life care [44] and the likelihood 
that such discussions will happen over time, separate to prognostic disclosure, [45] two 
ACP items were included in the final US QPL. 
  
Limitations and future directions 
Participants were recruited from 1 US and 2 Australian institutions. Consequently, 
participants’ attitudes may not represent general attitudes towards end-of-life focussed 
QPLs. Primary tumour site did not appear to influence patients’ responses, though this 
information was unavailable for all patients. The influence of factors such as diagnosis, 
age and gender on patients’ attitudes and experiences cannot be ruled out and a larger 
sample would allow sub-group analyses to discern the impact of such variables. 
 
All identified US patients agreed to participate, however seven Australian patients did not; 
one withdrew after consent believing study material to be too personal, one could not be 
contacted and five declined participation. Despite following stringent sampling procedures, 
bias introduced by enlisting oncologists to identify participants cannot be ruled out. 
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Patients who did not wish to discuss prognosis or end-of-life issues may also have refused 
participation, resulting in a biased sample.  
 
Future studies could test the generalisability of these findings and seek the input of 
patients’ significant others, including primary informal carers, who also participate in end-
of-life discussions. Randomised controlled trial evaluation of the QPL and development 
and evaluation for other populations and healthcare systems is also warranted. Finally, 
while some participants’ views on optimal timing of QPL delivery emerged during the 
interviews, this information was not universally available. Given the importance of timing in 
such discussions, [6] further investigation of appropriate delivery of an end-of-life focussed 
QPL is warranted.    
 
Conclusion and clinical implications 
The end-of-life focussed QPL for patients with advanced cancer in the last year of life was 
well accepted and endorsed by patients and health professionals alike. Two versions 
accommodating differences in Australian and US approaches to discussions of prognosis 
and end-of-life issues were evaluated. This study underscores the appropriateness of 
tailoring communication aides and interventions, such as QPLs, to individual populations. 
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Table 1 
Patient demographic and disease characteristics 
 Australian 
(n = 15a) 
US 
(n = 19a) 
Age  
  Mean 
  Range 
 
 
 67.6 
 54-86 
 
 58 
 34-75 
  N (%)   
 Australian US 
Gender  
  Male 
  Female 
 
 12 (80) 
 3 (20) 
 
 6 (31.6) 
 13 (68.4) 
Education  
  Year 10 or below/elementary/some high school 
  Year 12/HSC/GED/high school graduate 
  Professional qualification/some university/college 
  Undergraduate degree 
  Postgraduate degree 
 
 3 (20) 
 2 (13.3) 
 8 (53.3) 
 1 (6.7) 
 1 (6.7) 
 
 3 (15.8) 
 5 (26.3) 
 4 (21) 
 5 (26.3) 
 1 (5.3) 
Primary tumour site 
  Lung 
  Bladder 
  Prostate 
  Kidney 
 
 9 (60) 
 1 (6.7) 
 4 (26.6) 
 1 (6.7) 
 
Treatments received  
  Chemotherapy 
  Radiotherapy 
  Surgery 
 
 11 (73.3) 
 6 (40) 
 7 (46.7) 
 
a n varies due to missing data. Individual data for primary tumour site and treatments received were not 
collected for US patients 
 
Table 2 
Health professional demographic, specialty and training characteristics 
 Australian 
(n = 7b) 
US 
(n = 6b) 
Age 
  Mean 
  Range 
 
 45.3 
 39-50 
 
Experience 
  Mean 
  Range 
 
 
 13.3 
 2.5-26 
 
 16.5 
 1-27 
  N (%)  
 Australian US 
Gender 
  Male 
  Female 
 
 4 (57.1) 
 3 (42.9) 
 
 2 (33.3) 
 4 (66.7) 
Specialty 
  Medical Oncology 
  Radiation Oncology 
  Surgery 
  Nursing 
 
 2 (28.6) 
 1 (14.3) 
 0 (0) 
 4 (57.1) 
  
 6 (100) 
 0 (0) 
 0 (0) 
 0 (0) 
Tumour stream specialty 
  Lung 
  Genitourinary 
  Gastrointestinal 
  Lymphoma/Leukaemia 
  Brain 
 
 1 (33.3) 
 2 (66.7) 
 1 (33.3) 
 0 (0) 
 0 (0) 
 
 0 (0) 
 1 (16.7) 
 1 (16.7) 
 3 (50) 
 1 (16.7) 
Postgraduate communication training 
  No 
  Yes 
 
 4 (57.1) 
 3 (52.9) 
 
 4 (66.7) 
 2 (33.3) 
b n varies due to missing data and age data was not collected from US health professionals 
 28 
Appendix 1 
Australian and US Initial Question Prompt Lists 
Australian Initial Version US Initial Version 
Title: Asking questions: What now and what next… Title: Asking questions: What now and what next… 
Introduction: Most people who see their oncologist after treatment have 
questions and concerns, particularly when there are changes in their condition. 
Often these important questions are forgotten during a busy consultation, only to 
be remembered later on. The purpose of this question list is to help you to get 
the information that you want about your illness and what you can expect in the 
future. 
 
We have put this list of questions together after discussion with patients and their 
carers as well as doctors and other health care professionals. Your doctor will be 
happy to try to answer any questions you have now or in the future.  
 
You may like to circle the questions you want answered and add any of your own 
in the space provided. Your doctor may answer some of your questions without 
you even asking.  
 
We have organised this booklet into topics. You may find that some of these 
topics or some of the questions are not relevant to you at the moment. There 
may also be some topics or questions that you do not want to read about right 
now. We suggest that you read the headings first and then decide if you would 
like to look at the questions for each topic. Feel free to show this list to your 
family members. 
 
You can use this booklet as a checklist while you are seeing your doctor so that 
you can be sure that you have covered everything that is important to you. 
 
Different people want different things at different times. You might like to use this 
question list during this consultation, or at another time, or even with another 
member of you medical care team. You or your family may also find it helpful to 
refer to it in the future. Please do not feel that you have to ask any of these 
questions just because they are listed here. 
Introduction: To help your doctor focus on your concerns, choose the three of 
four questions that are most important. Ask them early in the visit. You may want 
to circle the question your want answered and add any of your own. 
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Australian Initial Version US Initial Version 
Section 1: My cancer and what to expect in the future 
• What is currently happening with my cancer? 
• What can I expect in the future? 
• Will this cancer shorten my life? 
• Is it possible to give me a time frame? How long can I expect to live? 
• What is the best-case scenario? What is the worst-case scenario? 
My cancer 
• What type of cancer is it? 
• Is it local or has it spread? 
• Do I need to do any other test to find out how far it has spread? 
Section 2: My treatment options 
Treating my cancer 
• What options are available to treat my cancer? 
• What are the aims of treatment for my cancer? 
• What are the pros and cons of further treatment for my cancer? 
• How likely is it that these treatments will shrink my cancer? 
• If the treatment works, will I live longer? 
• How much do these treatments cost? 
 
  Treating my symptoms 
• Will these treatments make me feel better or worse? 
• Can I also have treatments to help me to feel better? 
• What options are available to control things like pain, anxiety or nausea? 
   
  Palliative care 
• What is palliative care and do you think it might help me? 
• When would it be helpful for me to see someone from the palliative care 
team? 
Treating my cancer 
• What are the aims of treatment for my cancer? 
o To cure it? 
o To shrink it? 
o To slow it down? 
o To get rid of symptoms like pain? 
• How can I tell if my current treatment is working? 
• How likely is it that further treatments will work? 
• Should I consider a new or experimental therapy? 
• Before deciding, are there any other professionals I should talk to? (such as 
other doctors or clergy) 
Section 3: Making decisions about treatment 
  Making a decision… 
• Should I consider stopping anti-cancer treatments now and focus more 
on treatments to make me feel better? 
• Is there anyone else I should talk to before making these decisions? 
(e.g. other doctors, organizations, websites) 
• Should I think about alternative treatments? 
• What happens if I can’t afford the treatment? 
 
  After I’ve made my decision… 
• If I decide not to have anti-cancer treatment, who will look after me? 
• If I decide not to have anti-cancer treatment, can I still see you? 
• Will you tell my GP and the other doctors looking after me about my 
decisions? 
Treating my symptoms 
• How will further treatments make me feel? 
• Are there treatments to help me to manage pain, fatigue, nausea, or other 
symptoms? 
• Would it make sense for me to see a specialist in pain and symptom control? 
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Section 4: My life, my family and making plans 
• How can I make the most of my life, living with this cancer? 
• Are there any lifestyle changes that may help me make the most of my 
life, living with this cancer? (e.g. diet, exercise) 
• What can I expect to be able to do in the future? (e.g. working, driving, 
holidays) 
What I can expect 
• What can I expect to be able to do in the future? (e.g. working, driving, 
travelling, holidays) 
• Will this cancer shorten my life? 
• Is it possible to give me a time frame? 
• What is the best-case scenario? 
• What is the worst-case scenario? 
Section 5: Support for me and my family 
 Support for me 
• What support is available for me? 
• What information is available about my future care and what is 
happening to me? (e.g. books, videos, pamphlets) 
• Are there any organizations or services that would be useful for my carer 
or me to contact? (e.g. support organizations, respite care, disability 
parking) 
• What financial assistance is available for my carer or me? 
• Who can I talk to about my spiritual, religious and emotional needs? 
 
Support for my family 
• How can I help my family and children understand what is happening? 
Can someone help me to do this? 
• What support is available now and in the future for my carer, my children 
and my family? 
• What should I do if members of my family disagree about my decisions? 
What I can do 
• What can help me get the most out of my life (eg, diet, exercise, meditation, 
massage, support groups, etc.)? 
• Are there any specific materials patients like me have found useful (eg, 
books, videos, pamphlets)? 
• Are there any organizations or services that would be useful for me or my 
caregiver (such as support organizations, social services, disability parking)? 
Section 6: Preparing for the end of life 
• Who can I talk to about preparing for the end of life? 
• Is there a way to document my wishes for care at the end of life? 
• Should I appoint someone to make medical decisions on my behalf in 
case of emergency situations or if I am too unwell to speak for myself? 
• Is there anything I need to do to make these arrangements official? 
• How can I make sure that others involved in my care know my wishes? 
• What can I do to sort out my personal matters and write my will?  
If treatment doesn’t work 
• Who will be my doctor if I stop getting chemotherapy or radiation? 
• What is… 
o Palliative care? 
o Hospice? 
o What is the difference? 
• How will I know if I need to talk about the end of life? 
• What will likely happen at the very end? Will I be in a lot of pain or other 
discomfort? 
 31 
Australian Initial Version US Initial Version 
Section 7: Other questions your family and/or carer may like to ask 
• What skills will I need to support the person I am caring for? 
• What can I do to look after myself whilst caring for my 
partner/relative/friend? 
• Who can I talk to if I am concerned about the care my 
partner/relative/friend is receiving? 
• What help can I get if I can’t cope with caring for my 
partner/relative/friend? 
Concerns of family members and/or caregivers 
• How can I help my family and children understand what is happening? Can 
someone help me do this? 
• What skills will they need to help take care of me? 
• What can they do to cope and care for themselves while caring for me? 
• Who can they talk to if they are concerned about me or my care? 
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Appendix 2 
Australian and US Final Question Prompt Lists 
Australian Final Version US Final Version 
Title: Conversations with your doctor: Discussing your care as cancer 
progresses – a list of useful questions Title: Asking questions: What now and what next 
Introduction - Asking Questions: What Now and What Next… 
 
Getting information about what is currently happening with your cancer and what 
you can expect in the future can be challenging. Most people have concerns they 
wish to raise with their oncologist, particularly when there are changes in their 
condition. It can be difficult, however, to work out what questions to ask. Often 
these important questions are forgotten during a busy consultation, only to be 
remembered later on. 
 
Thinking about the questions you would like to ask your oncologist and writing 
them down before the consultation can be extremely helpful. To assist with this, 
we have listed some of the questions that patients, carers and health 
professionals have found useful in a situation similar to yours. 
 
We have divided the questions into topics, some of which may be more relevant 
to you now and others more relevant to you later. You can ask the questions 
word for word or use them as a checklist of things you want to find out. We 
suggest that you read through all of the questions and tick the ones you think 
you would like to ask now. There is also space on each page for you to add your 
own questions or notes. 
 
It may be helpful for you to prioritise your questions, as you may not get to ask 
them all at once and some may be more important to you than others. Also, feel 
free to share this list with your family members or friends; they may have 
questions of their own. 
 
You might like to use this list of questions during your next oncology 
consultation, at a later time, or even with another member of your health care 
team. Your questions and concerns can help your oncologist understand what 
your priorities are and work out what is best for you. He or she will be happy to 
try to answer any questions you have at any stage and may even answer some 
of your questions without you even asking. 
 
We encourage you to communicate your questions and concerns to your 
oncologist and health care team. Please do not feel, though, that you have to ask 
and of these questions just because we have listed them here. 
Introduction 
 
Most people who see their oncologist have questions and concerns. It’s very 
common to forget important questions during an office visit, only to wish you had 
remembered to ask them later on.  
 
This booklet can help you to get the information you want about your cancer and 
what you can expect in the future. 
 
We put this list of questions together after discussion with patients, their families 
and their caregivers as well as doctors and other health care professionals. 
These questions can help your doctor to answer any questions you have now or 
in the future. 
 
How to use this booklet 
 
We have organized this booklet into topics. You may find that some of these 
topics or questions are not relevant to you at the moment. There may also be 
some topics or questions you do not want to think about right now. Read the 
headings first and then decide if you would like to look at the questions for each 
topic.  
 
Feel free to show this list to your family. They might find it helpful, too. 
 
Remember that time is limited, so pick the questions that are the most important 
to you. 
 
You might like to use this question list during this office visit, or at another time, 
or even with another member of your medical care team.  
 
You or your family may also find it helpful to refer to it in the future. Different 
people want different things at different times. Please do not feel that you have to 
ask any of these questions just because they are listed here. 
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Section 1: My cancer and what to expect in the future 
• What is currently happening with my cancer? 
• What can I expect in the future? 
• Will this cancer shorten my life? 
• Is it possible to give me a time frame? How long can I expect to live? 
• What is the best-case scenario? What is the worst-case scenario? 
My cancer 
• What kind of cancer do I have? 
• What is currently happening with my cancer? 
• What are the main aims of treatment for my cancer? 
o To help me live longer (slow the cancer, remission or cure)? 
o To improve quality of life and improve symptoms (like pain)? 
• Is it still possible to cure my cancer? 
Section 2: Treating my cancer 
• What options are available to treat my cancer? 
• What are the pros and cons of further treatment for my cancer? 
• Is it still possible to cure my cancer? 
• How likely is it that these treatments will control my cancer? 
• If the treatment works, will I live longer? 
• Will these treatments make me feel better or worse? 
Treating my cancer 
• What are the benefits and side effects of further treatment for my cancer? 
• How likely is it that the cancer treatments will make me feel better? Control 
my cancer? Live longer? 
• How will I know that treatment is working? 
• Are treatments covered by insurance? 
Section 3: Palliative Care 
• What options are available to control things like pain, anxiety or nausea? 
• What is palliative care and do you think it might help me? 
• When would it be helpful for me to see someone from the palliative care 
team? 
Treating my symptoms 
• What treatments can help me manage my symptoms? 
o Pain 
o Nausea, diarrhoea 
o Fatigue 
o Depression, anxiety 
o Other symptoms? 
• How long might these treatments take to work? 
• Would it make sense for me to see a specialist in pain and symptoms control 
(such as palliative care or pain clinic)? 
Section 4: Making a decision… 
• Should I consider stopping anti-cancer treatments now and focus more on 
treatments to make me feel better? 
• Is there anyone else I should talk to before making these decisions? (e.g. 
other doctors, organizations, websites) 
• Will you tell my GP and the other doctors looking after me about my 
decisions? 
What I can expect 
• What can I expect to be able to do in the future? (e.g. working, driving, 
travelling, holidays) 
• Will this cancer shorten my life? 
• Is it possible to give me a time frame? 
• What is the best-case scenario? The worst-case scenario? 
• What is likely to happen at the very end? How could I prepare for that time? 
Section 5: My lifestyle 
• Are there any lifestyle changes that may help me make the most of my life, 
living with this cancer? (e.g. diet, exercise) 
• What can I expect to be able to do in the future? (e.g. working, driving, 
holidays) 
Preparing for the future 
• How can I be sure that my family and my physicians know my wishes about 
treatments in case I am unable to decide for myself? 
• Should I complete a health care proxy and/or living will form? 
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Section 6: Support for me 
• If I decide not to have anti-cancer treatment, who will look after me? 
• If I decide not to have anti-cancer treatment, can I still see you? 
• What other support is available for me? 
• What information is available about my future care and what is happening to 
me? (e.g. books, videos, pamphlets) 
• Are there any organisations or services that would be useful for my carer or 
me to contact? (e.g. support organisations, respite care, disability parking) 
• What financial assistance is available for my carer or me? 
• Who can I talk to about my spiritual, religious and emotional needs? 
What I can do 
Sometimes a nurse, social worker, physical therapist, or nutritionist might be able 
to help you with these questions *(marked with an asterisk): 
∗ What can help me feel better? (e.g. diet, exercise, meditation, massage, 
support groups, etc.) 
∗ Are there any therapies you think I should stay away from? 
∗  How can I learn more? (e.g. books, videos, pamphlets) 
∗ Are there any organizations or services that would be useful for me or my 
caregiver? (e.g. support organizations, social services, disability parking) 
Section 7: Support for my family 
• How can I help my family and children understand what is happening? Can 
someone help me to do this? 
• What support is available now and in the future for my carer, my children and 
my family? 
• What should I do if members of my family disagree about my decisions? 
If cancer treatment isn’t working 
• Should I consider stopping anti-cancer treatments and focus more on 
treatments to make me feel better? 
• Should I consider experimental therapy or clinical trial? A second opinion? 
• Who will be my doctor if I stop getting chemotherapy or radiation? 
• What is hospice? How will I know when I might need to consider hospice? 
Section 8: Making sure my wishes are honoured 
• Is there a way to plan and document my wishes for care at the end of life? 
• If my wishes change, how do I make sure people know and respect that? 
• Should I appoint someone to make medical decisions on my behalf in case 
of emergency situations or if I am too unwell to speak for myself? 
• Is there anything I need to do to make these arrangements official? 
• How can I make sure that others involved in my care know my wishes? 
Your family might like to ask 
• How can I help my family and children understand what is happening? Can 
someone help me do this? 
• What skills will I need to care for my family member with cancer? 
• Are there reading materials for me? 
• Who can I talk to if I am concerned about my loved one’s care? 
Section 9: Other questions your family, friends or carer may like to ask 
• What skills will I need to support the person I am caring for? 
• What can I do to look after myself whilst caring for my partner/relative/friend? 
• Who can I talk to if I am concerned about the care my partner/relative/friend 
is receiving? 
• What help can I get if I can’t cope with caring for my partner/relative/friend? 
Remember… 
To help your doctor focus on your concerns: 
• Bring this booklet with you to your appointments 
• Because time is limited, circle 3 or 4 questions that re the most important to 
you for any one visit 
• Write down other questions you might have 
• Ask questions early in the visit to make sure that your doctor has time 
 
You can use this booklet as a checklist while you are seeing your doctor so you 
can be sure you have covered the most important questions to you and your 
family. 
 
 
